Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Fineline Cube Aug 18, 2026
Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Fineline Cube Aug 18, 2026
Policy / Regulatory

China’s NHC Launches Pilot Plan to Expand Wholly Foreign-Owned Hospital Sector

Fineline Cube Dec 2, 2024

The National Health Commission (NHC) has released the “Pilot Work Plan for Expanding the Wholly...

Company Drug

Hua Medicine’s Second-Generation GKA HM-002-1005 Completes Phase Ia Study in the US

Fineline Cube Dec 2, 2024

China-based Hua Medicine (HKG: 2552) has announced the successful completion of a Phase Ia study...

Company Drug

Shanghai MicuRx’s MRX-4/Contezolid Meets Primary Endpoint in Phase III cSSTI Study

Fineline Cube Dec 2, 2024

Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA: 688373) has announced that its Phase III study for...

Company Deals

CBC Group and Mubadala Acquire UCB’s Neurology and Allergy Business in China for $680 Million

Fineline Cube Dec 2, 2024

Singapore-based healthcare private equity firm CBC Group and Mubadala Investment Company, a global investment company...

Company Drug

Simcere Zaiming Launches Phase III Trial for SERD Inhibitor SIM0270 in Breast Cancer

Fineline Cube Dec 2, 2024

Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary, Simcere Zaiming, has announced the initiation of a...

Company Drug

Hua Medicine’s SENSITIZE Study Illuminates Dorzagliatin’s β-Cell Glucose Sensitivity Mechanism

Fineline Cube Dec 2, 2024

China-based innovative drug developer Hua Medicine (HKG: 2552), with operations in the US and Hong...

Company Deals

Sunflower Pharmaceutical Group to Establish Joint Lab with Peking University for Bacterial Enzyme Research

Fineline Cube Dec 2, 2024

China-based Sunflower Pharmaceutical Group Co., Ltd. (SHE: 002737) is poised to establish a joint laboratory...

Company Drug

Simcere Pharmaceutical’s Edaravone and Borneol Sublingual Tablets Approved for AIS Treatment in China

Fineline Cube Dec 2, 2024

China-based Simcere Pharmaceutical Group Limited (HKG: 2096) has announced receiving marketing approval from the National...

Company Drug

Shanghai Pharmaceuticals Concludes Phase II Study for I037 in Acute Ischemic Stroke

Fineline Cube Dec 2, 2024

Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607) has announced the completion of data...

Company Deals

Affinity (Shanghai) Secures Over RMB 400 Million in Series B2 Financing to Advance Oncology Drugs

Fineline Cube Dec 2, 2024

Affinity (Shanghai), the parent company of Shanghai Affinity Biopharmaceutical Co., Ltd., has reportedly raised upwards...

Company Deals Hospital

Abogen Biosciences and Ruijin Hospital Launch Ruijin Abogen Nucleic Acid Drug Research Institute

Fineline Cube Dec 2, 2024

China-based nucleic acid drug developer Suzhou Abogen Biosciences and Ruijin Hospital, a comprehensive Class 3A...

Company Drug

Henlius Biotech Initiates US Commercial Supply of Hanquyou, Biosimilar to Herceptin

Fineline Cube Dec 2, 2024

Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the initiation of commercial supply of its...

Company Drug

ImmuneOnco Biopharmaceuticals Receives NMPA Approval for Lupus Nephritis Phase II Study

Fineline Cube Dec 2, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541), a China-based biopharmaceutical company, has announced receiving approval from...

Company Drug

Healthgen Biotechnology’s Plant-Made Albumin Breakthrough: A Milestone in Serum Therapy

Fineline Cube Dec 1, 2024

On November 30th, Healthgen Biotechnology Corp. announced a significant research outcome at the 9th Pharmaceutical...

Company

Shanghai Cell Therapy Group’s Second Attempt at HK IPO Receives Green Light from CICC and CCB International

Fineline Cube Dec 1, 2024

Shanghai Cell Therapy Group Co., Ltd., a leading player in China’s cellular medical health sector,...

Company

Nanjing Leads Biolabs Commences IPO Process with Focus on Innovative Therapies

Fineline Cube Nov 30, 2024

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biopharmaceutical company focused on developing innovative therapies for...

Company Drug

XellSmart Bio-Pharmaceutical Achieves Milestone with First Patient Enrollment in Global iPSC Clinical Study for ALS

Fineline Cube Nov 30, 2024

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd., in collaboration with Shanghai East Hospital (Tongji University Affiliated East...

Company Drug

Cutia Therapeutic’s CU-20401 Shows Positive Results in Phase II Subcutaneous Fat Reduction Study

Fineline Cube Nov 29, 2024

China-based dermatology specialist Cutia Therapeutic (HKG: 2487) has revealed a positive readout from its Phase...

Company Deals

OBiO Technology Partners with Hanxin Biotechnology to Advance LNP Delivery System

Fineline Cube Nov 29, 2024

China-based gene therapy Contract Research Organization (CRO) OBiO Technology (Shanghai) Co., Ltd (SHA: 688238) has...

Company Medical Device

NMPA Approves Shenzhen Mindray’s Innovative Dual-Mode Ultrasound Diagnostic System

Fineline Cube Nov 29, 2024

The National Medical Products Administration (NMPA) has granted approval to Shenzhen Mindray Bio-Medical Electronics Co.,...

Posts pagination

1 … 299 300 301 … 709

Recent updates

  • OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties
  • European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
  • Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
  • Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors
  • CANbridge Pharmaceuticals’ Livmarli Granted NHIA Reimbursement Approval in Taiwan – IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.